AMO Pharma Limited

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, AMO Pharma Limited sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).

2 total trials 1 currently recruiting 1 completed early-phase tilt upper half by trial count

AMO Pharma Limited: 2 sponsored US clinical trials, 1 recruiting.

AMO Pharma Limited sponsors 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Congenital Myotonic Dystrophy, with 1 trials.

Mid-pack sponsor footprint

AMO Pharma Limited is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

What is open in the AMO Pharma Limited pipeline

1 recruiting of 2 indexed (50% open); 1 completed (50%).

Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).

Top condition: Congenital Myotonic Dystrophy (1 trial), 0 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

AMO Pharma Limited: open-pipeline peers nationwide

Peers matched on 2 registered trials and 50% open enrollment, not the therapeutic-area sidebar.

AMO Pharma Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1.522.533.544.5 0%20%40%60% Total trials Recruiting share AMO Pharma Limited1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO Health3ive Labs60 Degrees Pharmaceuticals7 Hills PharmaAbcentra
AMO Pharma Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

AMO Pharma Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 2 trials (± recruiting share)

Sponsors near 50% open enrollment (± trial volume)

What to do with this AMO Pharma Limited page

2 registered trials is a research-attention snapshot, not an endorsement of AMO Pharma Limited or any single study.

  • 1 of AMO Pharma Limited's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Congenital Myotonic Dystrophy is the condition AMO Pharma Limited studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Congenital Myotonic Dystrophy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

AMO Pharma Limited pipeline card: 2 registered trials from official public datasets.Report a data error.